413 related articles for article (PubMed ID: 17078855)
1. Selective priming of peripheral blood eosinophils in patients with idiopathic hypereosinophilic syndrome.
Lampinen M; Oberg G; Venge P; Carlson M
APMIS; 2006 Nov; 114(11):757-63. PubMed ID: 17078855
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-5 mRNA levels in blood and bone marrow mononuclear cells from patients with the idiopathic hypereosinophilic syndrome.
Satoh T; Sun L; Li MS; Spry CJ
Immunology; 1994 Oct; 83(2):308-12. PubMed ID: 7835952
[TBL] [Abstract][Full Text] [Related]
3. Presence of factors chemotactic for granulocytes in hypereosinophilic syndrome sera: relation with alterations in eosinophil migration.
Gosset P; Prin L; Capron M; Auriault C; Tonnel AB; Capron A
Clin Exp Immunol; 1986 Sep; 65(3):654-63. PubMed ID: 3780047
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome.
Simon HU; Plötz S; Simon D; Seitzer U; Braathen LR; Menz G; Straumann A; Dummer R; Levi-Schaffer F
Eur J Immunol; 2003 Apr; 33(4):834-9. PubMed ID: 12672048
[TBL] [Abstract][Full Text] [Related]
5. Priming of eosinophil and neutrophil migratory responses by interleukin 3 and interleukin 5.
Håkansson L; Venge P
APMIS; 1994 Apr; 102(4):308-16. PubMed ID: 8011308
[TBL] [Abstract][Full Text] [Related]
6. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
7. Study of release of eosinophil cationic proteins (ECP and EPX) in the hypereosinophilic syndrome (HES) and other hypereosinophilic conditions.
Bobbio-Pallavicini E; Confalonieri M; Tacconi F; Mainardi E; Della Porta R; Ceccato D; Maccario R; De Amici M
Panminerva Med; 1998 Sep; 40(3):186-90. PubMed ID: 9785914
[TBL] [Abstract][Full Text] [Related]
8. Migratory responses of eosinophil and neutrophil granulocytes from patients with asthma.
Håkansson L; Carlson M; Stålenheim G; Venge P
J Allergy Clin Immunol; 1990 Apr; 85(4):743-50. PubMed ID: 2324413
[TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of the interleukin 5 receptor alpha isoforms in blood and tissue eosinophils of nasal polyp patients.
Gevaert P; Hellman C; Lundblad L; Lundahl J; Holtappels G; van Cauwenberge P; Tavernier J; Bachert C
Allergy; 2009 May; 64(5):725-32. PubMed ID: 19170670
[TBL] [Abstract][Full Text] [Related]
11. Hypereosinophilic syndrome: case presentation and update.
Leiferman KM; Gleich GJ
J Allergy Clin Immunol; 2004 Jan; 113(1):50-8. PubMed ID: 14713907
[TBL] [Abstract][Full Text] [Related]
12. Genetic effect of CCR3 and IL5RA gene polymorphisms on eosinophilia in asthmatic patients.
Lee JH; Chang HS; Kim JH; Park SM; Lee YM; Uh ST; Rhim T; Chung IY; Kim YH; Park BL; Park CS; Shin HD
J Allergy Clin Immunol; 2007 Nov; 120(5):1110-7. PubMed ID: 17983872
[TBL] [Abstract][Full Text] [Related]
13. [Neurologic complications in hypereosinophilia syndrome--a case report].
Otto V
Fortschr Neurol Psychiatr; 1993 Sep; 61(9):310-2. PubMed ID: 7693561
[TBL] [Abstract][Full Text] [Related]
14. Increased chemokinetic and chemotactic responses of eosinophils in asthmatic patients.
Griffin E; Håkansson L; Formgren H; Jörgensen K; Venge P
Allergy; 1991 May; 46(4):255-65. PubMed ID: 1897687
[TBL] [Abstract][Full Text] [Related]
15. Expression of lacto-N-fucopentaose III (CD15)- and sialyl-Lewis X-bearing molecules and their functional properties in eosinophils from patients with the idiopathic hypereosinophilic syndrome.
Satoh T; Knowles A; Li MS; Sun L; Tooze JA; Zabucchi G; Spry CJ
Immunology; 1994 Oct; 83(2):313-8. PubMed ID: 7835953
[TBL] [Abstract][Full Text] [Related]
16. Interactions between eotaxin and interleukin-5 in the chemotaxis of primed and non-primed human eosinophils.
Costa GG; Silva RM; Franco-Penteado CF; Antunes E; Ferreira HH
Eur J Pharmacol; 2007 Jul; 566(1-3):200-5. PubMed ID: 17368616
[TBL] [Abstract][Full Text] [Related]
17. Plasma membrane antigens on light density and activated human blood eosinophils.
Tai PC; Bakes DM; Barkans JR; Spry CJ
Clin Exp Immunol; 1985 May; 60(2):427-36. PubMed ID: 4006306
[TBL] [Abstract][Full Text] [Related]
18. Eosinophils involved in fulminant hepatic failure are associated with high interleukin-6 expression and absence of interleukin-5 in liver and peripheral blood.
dos Santos DC; da Silva Gomes Martinho JM; Pacheco-Moreira LF; Carvalho Viana de Araújo C; Caroli-Bottino A; Pannain VL; Soares Trinta K; Gandini M; da Costa Neves PC; de Souza Matos DC; Gonçalves Caputo LF; Pelajo-Machado M; Alves Pinto M
Liver Int; 2009 Apr; 29(4):544-51. PubMed ID: 19323781
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
20. Eosinophil-selective mediators in human strongyloidiasis.
Mir A; Benahmed D; Igual R; Borrás R; O'Connor JE; Moreno MJ; Rull S
Parasite Immunol; 2006 Aug; 28(8):397-400. PubMed ID: 16879311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
